Results 251 to 260 of about 137,002 (346)

The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? [PDF]

Biomolecules
Kounatidis D, Vallianou NG, Rebelos E, Vallianou K, Diakoumopoulou E, Makrilakis K, Tentolouris N.   +6 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor (GLP1R; GLP-1R) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller, Linoy Gabay, Oren Barak, Alena Kirzhner, Haitham Abu Khadija, Gabriel Chodick, Edi Vaisbuch, Yael Barer   +7 more
wiley   +1 more source

Successful Use of Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis. [PDF]

ACG Case Rep J
Guralwar C, Mitsuhashi S, Ashkar M, Chedid VG.   +3 more
europepmc   +1 more source

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay, Dayana El Chaar, Melanie Paquette, Michael Vallis, Diana Sherifali, Paul Oh, Susan Marzolini, Kaberi Dasgupta, Gillian Booth, Mike Lean, Hertzel C. Gerstein, Jordi Salas‐Salvadó, Jacqueline L. Beaudry, Christopher P. F. Marinangeli, Russell J. de Souza, Lawrence A. Leiter, Cyril W. C. Kendall, David J. A. Jenkins, John L. Sievenpiper, Laura Chiavaroli   +19 more
wiley   +1 more source

Preoperative Glucagon-Like Peptide-1 Receptor Agonist Treatment to Allow Safe Laparoscopic Left Pancreatectomy in Extreme Obesity: The First Report. [PDF]

Case Rep Surg
Canali G, Herfeld G, Averous G, Baltzinger P, Addeo P.   +4 more
europepmc   +1 more source

Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost‐effectiveness modelling study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Coronary artery calcium (CAC) scoring is observed to improve risk stratification for major adverse cardiovascular events (MACE). Semaglutide, a recently introduced anti‐obesity drug, is very effective, but wider use is limited due to high costs.
Sai Rahul Ponnana, Tong Zhang, Santosh Kumar Sirasapalli, Zhuo Chen, Jean‐Eudes Dazard, Niketh Surya, Shamsa Elhussain, Kanimozhi Sivanantham, Robert Okyere, Ian J. Neeland, Sanjay Rajagopalan, Salil V. Deo   +11 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction. [PDF]

J Am Heart Assoc
Ibrahim R, Han W, Wang W, Kau E, Said N, Forst B, Pham HN, Abdelnabi M, Salih M, Ali NB, Farina J, Lester SJ, Lee K, Ayoub C, Arsanjani R.   +14 more
europepmc   +1 more source

Association of glucagon-like peptide-1 receptor agonists with risk of gastrointestinal adverse events: evidence from a drug target Mendelian randomization. [PDF]

Eur Heart J Cardiovasc Pharmacother
Huang H, Liu J, Lu X, Tan N, Liu Y.
europepmc   +1 more source